| Assessment Status | Rapid Review complete |
| HTA ID | - |
| Drug | Benralizumab |
| Brand | Fasenra® |
| Indication | As add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists. |
| Assessment Process | |
| Rapid review commissioned | 15/01/2018 |
| Rapid review completed | 14/02/2018 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended at the Submitted Price |
The HSE has approved reimbursement following confidential price negotiations; April 2019
